What is Bavarian Nordic A/S (BVNKF)?

Bavarian Nordic A/S (BVNKF) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of BVNKF?

The current price of BVNKF is $36.06. Prices are updated in real time on Stocks360.

What is BVNKF's price-to-earnings (PE) ratio?

BVNKF's trailing twelve-month PE ratio is 12.44, based on current price and earnings per share data available on Stocks360.

What is BVNKF's market capitalization?

BVNKF's market capitalization is $2,740,166,081.00, placing it in the mid-cap tier.

Bavarian Nordic A/S (BVNKF)

Stock analysis · OTC · Healthcare · Biotechnology

$36.06

Market Cap

$2.74B

PE (TTM)

12.44

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.94

Day Range

$27.56 – $36.06

52-wk Range

$27.56 – $37.02

Avg Volume

N/A

Volume

3.00

Bavarian Nordic A/S (BVNKF) is a publicly traded company in the Healthcare sector. Latest price: $36.06. Market cap $2.74B. Trailing PE 12.44. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $37.02 2026-10-30 · $36.06 (-2.59%)

Earnings

Most Recent

Aug 21, 2026

EPS $1.43 vs est. $0.48

Beat by $0.95

Next Earnings

Nov 13, 2026

EPS estimate $0.80

Proprietary Signals

Signal snapshot temporarily unavailable.

About Bavarian Nordic A/S

Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in cancer immunotherapy including cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian, and prostate cancer. The company was founded on July 1, 1992 and is headquartered in Hellerup, Denmark.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	12.44×
P/S (TTM)	2.96×
P/B	1.41×
PEG	1.25×
P/FCF (TTM)	15.06×
EV / EBITDA	6.86×
EV / Sales	2.86×
Earnings Yield	8.28%
Free Cash Flow Yield	6.64%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$18.00B
Revenue (TTM)	$6.30B
Net Income (TTM)	$1.54B
Free Cash Flow (TTM)	$1.15B
Net Debt	-$645.35M
Working Capital	$5.67B
Gross Margin	49.53%
Operating Margin	29.77%
Net Margin	24.50%
Return on Equity	11.88%
Return on Invested Capital	10.62%